U.S./Japan Free Trade Agreement Would Encourage Pharma Innovation, Lilly CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Taurel argues in favor of an open market that would ease Japan-specific clinical trial requirements.